Cytokinetics, Incorporated
NASDAQCytokinetics heads into its August 6 earnings report with a clear tension between an activist short base and a Street that remains broadly bullish on the cardiac drug story. The most striking pre-print signal is insider selling. Every recent transaction has been a sale. CEO Robert Blum has sold shares three times since July 1, raising over $1.85 million combined. The Chief…
Snapshot as of 6 Aug 2026
Cytokinetics heads into its August 6 earnings report with a clear tension between an activist short base and a Street that remains broadly bullish on the cardiac drug story. The most striking pre-print signal is…
Cytokinetics adds another layer to its bullish June narrative this week — a bellwether analyst upgrade colliding with call positioning at its most extreme reading of the past year. The Street catalyst is the sharpest…
Cytokinetics enters the back half of June with a stock up nearly 10% on the week and an options market that has decisively tilted toward call buyers — a combination that tells a cleaner bullish story than the short…
Cytokinetics delivered a sharp week of contrasts: a 27% price rally driven by a blowout Q1 revenue print, while insiders and the company itself rushed to lock in the gain. The catalyst was Tuesday's Q1 release. Revenue…
Cytokinetics heads into its Q1 2026 earnings report today with an unusual split: a 27% surge in the past week, and a parade of insider sellers cashing out at every step. The stock's move is striking. Shares closed at…
Cytokinetics heads into its May 5 Q1 print with one signal dominating the pre-earnings picture: insiders are selling, consistently, at every level of management. The CEO, CCO, and an EVP have all sold shares in April,…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for CYTK — free to start on ORTEX.
Sign up for free →Open CYTK on ORTEX